These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 39175540)

  • 1. Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia.
    Bian X; Liu W; Yang K; Sun C
    Front Pharmacol; 2024; 15():1421816. PubMed ID: 39175540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
    Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
    J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.
    Csizmar CM; Saliba AN; Swisher EM; Kaufmann SH
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34945003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
    Fritz C; Portwood SM; Przespolewski A; Wang ES
    Blood Rev; 2021 Jan; 45():100696. PubMed ID: 32482307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.
    Faraoni I; Giansanti M; Voso MT; Lo-Coco F; Graziani G
    Biochem Pharmacol; 2019 Sep; 167():133-148. PubMed ID: 31028744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
    Peyraud F; Italiano A
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.
    Wu Z; Cui P; Tao H; Zhang S; Ma J; Liu Z; Wang J; Qian Y; Chen S; Huang Z; Zheng X; Huang D; Hu Y
    Clin Med Insights Oncol; 2021; 15():1179554921996288. PubMed ID: 33737855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
    Faraoni I; Graziani G
    Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30518089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
    Hunia J; Gawalski K; Szredzka A; Suskiewicz MJ; Nowis D
    Front Mol Biosci; 2022; 9():1073797. PubMed ID: 36533080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    Papa A; Caruso D; Strudel M; Tomao S; Tomao F
    J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.
    Bound NT; Vandenberg CJ; Kartikasari AER; Plebanski M; Scott CL
    Front Genet; 2022; 13():886170. PubMed ID: 36159999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic Induction of BRCAness in
    Abbotts R; Dellomo AJ; Rassool FV
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    Kim DS; Camacho CV; Kraus WL
    Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.
    Esposito MT; Zhao L; Fung TK; Rane JK; Wilson A; Martin N; Gil J; Leung AY; Ashworth A; So CW
    Nat Med; 2015 Dec; 21(12):1481-90. PubMed ID: 26594843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
    J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.